Reporter brief
Phase IIa trial evaluates safety and feasibility of subretinal OpRegen stem cell delivery in geographic atrophy.
What happened
This Phase IIa open-label single-arm study assessed the surgical feasibility and safety of subretinal delivery of OpRegen (a stem cell therapy) in patients with geographic atrophy secondary to age-related macular degeneration. The trial also evaluated preliminary activity of the intervention. A substudy explored incorporation of advanced retinal imaging as an assessment tool.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Other; Human.
Participants with geographic atrophy secondary to age-related macular degeneration
- Design
- Other
- Sample
- —
- Journal
- Genentech, Inc.
- Published
- Sep 15, 2026
Effect size
Not recorded.
Caveats
- Assessment: Pending.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Genentech, Inc.
Previous evidence
See the Stem cell therapy timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.